{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:00:55Z","timestamp":1792036855656,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82425002"],"award-info":[{"award-number":["82425002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900104"],"award-info":[{"award-number":["81900104"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82130003"],"award-info":[{"award-number":["82130003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Key Research and Development Program of Zhejiang Province"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41409-025-02769-x","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T14:27:30Z","timestamp":1765636050000},"page":"312-321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive values of baseline 18F-FDG PET\/CT for toxicities and outcomes in patients with relapsed or refractory multiple myeloma following BCMA CAR T-cell therapy"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5425-8623","authenticated-orcid":false,"given":"Pingnan","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhen","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Hongsheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-1621","authenticated-orcid":false,"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9564-1852","authenticated-orcid":false,"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"2769_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13045-020-00980-5","volume":"13","author":"Y Yang","year":"2020","unstructured":"Yang Y, Li Y, Gu H, Dong M, Cai Z. Emerging agents and regimens for multiple myeloma. J Hematol Oncol. 2020;13:150 https:\/\/doi.org\/10.1186\/s13045-020-00980-5.","journal-title":"J Hematol Oncol"},{"key":"2769_CR2","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1817226.","journal-title":"N Engl J Med"},{"key":"2769_CR3","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, et al. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022;387:1196\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2209900.","journal-title":"N Engl J Med"},{"key":"2769_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2024850.","journal-title":"N Engl J Med"},{"key":"2769_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388\u201398. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0548.","journal-title":"Cancer Discov"},{"key":"2769_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8.","journal-title":"Lancet"},{"key":"2769_CR7","doi-asserted-by":"publisher","first-page":"630 e631","DOI":"10.1016\/j.jtct.2024.03.003","volume":"30","author":"L Caillot","year":"2024","unstructured":"Caillot L, Sleiman E, Lafon I, Chretien ML, Gueneau P, Payssot A, et al. Early chimeric antigen receptor T cell expansion is associated with prolonged progression-free survival for patients with relapsed\/refractory multiple myeloma treated with Ide-Cel: a retrospective monocentric study. Transpl Cell Ther. 2024;30:630 e631\u2013630 e638. https:\/\/doi.org\/10.1016\/j.jtct.2024.03.003.","journal-title":"Transpl Cell Ther"},{"key":"2769_CR8","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.1158\/1078-0432.CCR-21-2031","volume":"27","author":"M Zhang","year":"2021","unstructured":"Zhang M, Zhou L, Zhao H, Zhang Y, Wei G, Hong R, et al. Risk factors associated with durable progression-free survival in patients with relapsed or refractory multiple myeloma treated with anti-BCMA CAR T-cell therapy. Clin Cancer Res. 2021;27:6384\u201392. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2031.","journal-title":"Clin Cancer Res"},{"key":"2769_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","volume":"16","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J Hematol Oncol. 2023;16:88 https:\/\/doi.org\/10.1186\/s13045-023-01465-x.","journal-title":"J Hematol Oncol"},{"key":"2769_CR10","doi-asserted-by":"publisher","unstructured":"Chen R, Jin C, Liu K, Zhao M, Yang T, Zhang M et al. Predictive value of pre-treatment circulating tumor DNA genomic landscape in patients with relapsed\/refractory multiple myeloma undergoing anti-BCMA CAR-T therapy: Insights from tumor cells and T cells. Chin Med J (Engl). 2024. https:\/\/doi.org\/10.1097\/CM9.0000000000003306.","DOI":"10.1097\/CM9.0000000000003306"},{"key":"2769_CR11","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1182\/bloodadvances.2024014360","volume":"9","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Tormo-Ratera M, Oliver-Caldes A, Soler-Perromat JC, Gonzalez-Calle V, Moreno DF, et al. Clinical impact of [18F]FDG-PET\/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed\/refractory multiple myeloma. Blood Adv. 2025;9:571\u201382. https:\/\/doi.org\/10.1182\/bloodadvances.2024014360.","journal-title":"Blood Adv"},{"key":"2769_CR12","doi-asserted-by":"publisher","unstructured":"Jin C, Chen R, Fu S, Zhang M, Teng Y, Yang T et al. Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed\/refractory multiple myeloma. J Immunother Cancer. 2025; 13. https:\/\/doi.org\/10.1136\/jitc-2024-010687.","DOI":"10.1136\/jitc-2024-010687"},{"key":"2769_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00277-019-03852-2","volume":"99","author":"R Fonti","year":"2020","unstructured":"Fonti R, Pellegrino S, Catalano L, Pane F, Del Vecchio S, Pace L. Visual and volumetric parameters by 18F-FDG-PET\/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma. Ann Hematol. 2020;99:127\u201335. https:\/\/doi.org\/10.1007\/s00277-019-03852-2.","journal-title":"Ann Hematol"},{"key":"2769_CR14","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of (18)F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18:e206\u2013e217. https:\/\/doi.org\/10.1016\/S1470-2045(17)30189-4.","journal-title":"Lancet Oncol"},{"key":"2769_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12149-022-01812-x","volume":"37","author":"B Wan","year":"2023","unstructured":"Wan B, Zhang S, Wang P, Deng P, Dai W. Prognostic value of semi-quantitative parameters of (18)F-FDG PET\/CT in newly diagnosed multiple myeloma patients. Ann Nucl Med. 2023;37:155\u201365. https:\/\/doi.org\/10.1007\/s12149-022-01812-x.","journal-title":"Ann Nucl Med"},{"key":"2769_CR16","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1158\/1078-0432.CCR-16-0235","volume":"23","author":"JE McDonald","year":"2017","unstructured":"McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, et al. Assessment of total lesion glycolysis by (18)F FDG PET\/CT significantly improves prognostic value of GEP and ISS in myeloma. Clin Cancer Res. 2017;23:1981\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0235.","journal-title":"Clin Cancer Res"},{"key":"2769_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70159","volume":"9","author":"P Born","year":"2025","unstructured":"Born P, Fandrei D, Wang SY, Perez-Fernandez C, Fischer L, Ussmann J, et al. Prognostic significance of PET\/CT for CAR T cell therapy in relapsed\/refractory multiple myeloma. Hemasphere. 2025;9:e70159. https:\/\/doi.org\/10.1002\/hem3.70159.","journal-title":"Hemasphere"},{"key":"2769_CR18","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","volume":"25","author":"J Wang","year":"2019","unstructured":"Wang J, Hu Y, Yang S, Wei G, Zhao X, Wu W, et al. Role of fluorodeoxyglucose positron emission tomography\/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with Non-Hodgkin lymphoma. Biol Blood Marrow Transpl. 2019;25:1092\u20138. https:\/\/doi.org\/10.1016\/j.bbmt.2019.02.008.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2769_CR19","doi-asserted-by":"publisher","first-page":"713577","DOI":"10.3389\/fonc.2021.713577","volume":"11","author":"R Hong","year":"2021","unstructured":"Hong R, Tan Su Yin E, Wang L, Zhao X, Zhou L, Wang G, et al. Tumor burden measured by 18F-FDG PET\/CT in predicting efficacy and adverse effects of chimeric antigen receptor T-cell therapy in Non-Hodgkin lymphoma. Front Oncol. 2021;11:713577 https:\/\/doi.org\/10.3389\/fonc.2021.713577.","journal-title":"Front Oncol"},{"key":"2769_CR20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188\u201395. https:\/\/doi.org\/10.1182\/blood-2014-05-552729.","journal-title":"Blood"},{"key":"2769_CR21","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"key":"2769_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:387\u2013405. https:\/\/doi.org\/10.6004\/jnccn.2022.0020.","journal-title":"J Natl Compr Canc Netw"},{"key":"2769_CR23","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1182\/bloodadvances.2019001304","volume":"4","author":"SJ Schuster","year":"2020","unstructured":"Schuster SJ, Maziarz RT, Rusch ES, Li J, Signorovitch JE, Romanov VV, et al. Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv. 2020;4:1432\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2019001304.","journal-title":"Blood Adv"},{"key":"2769_CR24","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130:2295\u2013306. https:\/\/doi.org\/10.1182\/blood-2017-06-793141.","journal-title":"Blood"},{"key":"2769_CR25","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1407222.","journal-title":"N Engl J Med"},{"key":"2769_CR26","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6:664\u201379. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0040.","journal-title":"Cancer Discov"},{"key":"2769_CR27","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739\u201348. https:\/\/doi.org\/10.1038\/s41591-018-0036-4.","journal-title":"Nat Med"},{"key":"2769_CR28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transpl. 2019;25:625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758. e-pub ahead of print 2018\/12\/29.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2769_CR29","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8:958\u201371. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1319.","journal-title":"Cancer Discov"},{"key":"2769_CR30","doi-asserted-by":"publisher","unstructured":"Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020; 8. https:\/\/doi.org\/10.1136\/jitc-2020-001511.","DOI":"10.1136\/jitc-2020-001511"},{"key":"2769_CR31","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","volume":"4","author":"EA Dean","year":"2020","unstructured":"Dean EA, Mhaskar RS, Lu H, Mousa MS, Krivenko GS, Lazaryan A, et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4:3268\u201376. https:\/\/doi.org\/10.1182\/bloodadvances.2020001900.","journal-title":"Blood Adv"},{"key":"2769_CR32","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","volume":"74","author":"RM Alvi","year":"2019","unstructured":"Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol. 2019;74:3099\u2013108. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.038.","journal-title":"J Am Coll Cardiol"},{"key":"2769_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","volume":"2","author":"AK Ghosh","year":"2020","unstructured":"Ghosh AK, Chen DH, Guha A, Mackenzie S, Walker JM, Roddie C. CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity?. JACC CardioOncol. 2020;2:97\u2013109. https:\/\/doi.org\/10.1016\/j.jaccao.2020.02.011.","journal-title":"JACC CardioOncol"},{"key":"2769_CR34","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404\u201319. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0698.","journal-title":"Cancer Discov"},{"key":"2769_CR35","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1182\/blood-2018-05-846428","volume":"132","author":"A Nellan","year":"2018","unstructured":"Nellan A, McCully CML, Cruz Garcia R, Jayaprakash N, Widemann BC, Lee DW, et al. Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques. Blood. 2018;132:662\u20136. https:\/\/doi.org\/10.1182\/blood-2018-05-846428.","journal-title":"Blood"},{"key":"2769_CR36","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1038\/sj.cdd.4401456","volume":"11","author":"S Schmidt","year":"2004","unstructured":"Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ. 2004;11:S45\u201355. https:\/\/doi.org\/10.1038\/sj.cdd.4401456.","journal-title":"Cell Death Differ"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02769-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02769-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02769-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:56:08Z","timestamp":1772808968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02769-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2769"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02769-x","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Competing Interests: Authors Yanlei Z and AHC are employed by Shanghai YaKe Biotechnology. However, the other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol received approval from the Institutional Review Board of the First Affiliated Hospital, School of Medicine, Zhejiang University (IIT2018747-8). All participants provided written informed consent prior to their enrollment in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent statements"}}]}}